By analysing these molecular interactions, we aim to uncover potential therapeutic targets that could disrupt this axis, thereby inhibiting the stem-like properties of cancer cells and improving treatment outcomes for patients with HER2-positive breast cancer. Here, ERBB2 is linked to breast carcinoma.